Literature DB >> 16076005

P53 in cancer: a paradigm for modern management of cancer.

R J C Steele1, D P Lane.   

Abstract

The p53 tumour suppressor gene is thought to be central in protecting against the development of cancer, and this article reviews current understanding of its function and potential clinical significance. Information for this review was obtained from previous review articles, references cited in original papers, a Pubmed search of the last twelve months' literature and by scanning the latest issues of relevant journals. P53 can be described as a stress response gene, its product (the p53 protein) acting to induce apoptosis or cell-cycle arrest in response to DNA damage, thereby maintaining genetic stability in the organism. These functions are realised by a series of steps known as the "p53 pathway" involving induction of the expression of a number of other genes. As p53 is the most commonly mutated gene in human cancer, it has attracted a great deal of interest in the areas of prognosis, diagnosis and therapy, and p53 gene therapy is becoming established as a useful adjunct to conventional cancer treatment.

Entities:  

Mesh:

Year:  2005        PMID: 16076005     DOI: 10.1016/s1479-666x(05)80041-1

Source DB:  PubMed          Journal:  Surgeon        ISSN: 1479-666X            Impact factor:   2.392


  15 in total

1.  Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.

Authors:  Ernest S Han; Robert A Burger; Kathleen M Darcy; Michael W Sill; Leslie M Randall; Dana Chase; Basmina Parmakhtiar; Bradley J Monk; Benjamin E Greer; Patrick Connelly; Koen Degeest; John P Fruehauf
Journal:  Gynecol Oncol       Date:  2010-09-25       Impact factor: 5.482

2.  p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor.

Authors:  Dora Bocangel; Shiladitya Sengupta; Sankar Mitra; Kishor K Bhakat
Journal:  Anticancer Res       Date:  2009-10       Impact factor: 2.480

3.  COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer.

Authors:  Johanna Mrena; Jan-Patrik Wiksten; Arto Kokkola; Stig Nordling; Ari Ristimäki; Caj Haglund
Journal:  Tumour Biol       Date:  2009-12-18

4.  SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer.

Authors:  Shu-Jing Yu; Jie-Kai Yu; Wei-Ting Ge; Han-Guang Hu; Ying Yuan; Shu Zheng
Journal:  World J Gastroenterol       Date:  2011-04-21       Impact factor: 5.742

5.  The predictive value of genes of the TGF-beta1 pathway in multimodally treated squamous cell carcinoma of the esophagus.

Authors:  Franziska Pühringer-Oppermann; Mario Sarbia; Nicola Ott; Björn L D M Brücher
Journal:  Int J Colorectal Dis       Date:  2009-12-15       Impact factor: 2.571

6.  p53, sex, and aging: lessons from the fruit fly.

Authors:  Jae H Hur; David W Walker
Journal:  Aging (Albany NY)       Date:  2009-11-13       Impact factor: 5.682

7.  The association between selected risk factors for pancreatic cancer and the expression of p53 and K-ras codon 12 mutations.

Authors:  Jon P Fryzek; David H Garabrant; Maryjean Schenk; Margaret Kinnard; Joel K Greenson; Fazlul H Sarkar
Journal:  Int J Gastrointest Cancer       Date:  2006

8.  Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53.

Authors:  A K Arya; A El-Fert; T Devling; R M Eccles; M A Aslam; C P Rubbi; N Vlatković; J Fenwick; B H Lloyd; D R Sibson; T M Jones; M T Boyd
Journal:  Br J Cancer       Date:  2010-06-29       Impact factor: 7.640

9.  Regulation of the human AP-endonuclease (APE1/Ref-1) expression by the tumor suppressor p53 in response to DNA damage.

Authors:  Amira Zaky; Carlos Busso; Tadahide Izumi; Ranajoy Chattopadhyay; Ahmad Bassiouny; Sankar Mitra; Kishor K Bhakat
Journal:  Nucleic Acids Res       Date:  2008-01-21       Impact factor: 16.971

10.  A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.

Authors:  Sang-Soo Kim; Antonina Rait; Eric Kim; Kathleen F Pirollo; Esther H Chang
Journal:  Nanomedicine       Date:  2014-09-18       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.